|
Patent landscape, scope, and claims: |
Analysis of United States Drug Patent 11,872,218
This report analyzes United States Patent 11,872,218, focusing on its scope, claims, and the surrounding patent landscape for the claimed pharmaceutical compounds and their therapeutic applications. The patent, granted on January 16, 2024, to Eli Lilly and Company, claims novel pharmaceutical compositions containing specific pyrazolopyrimidine derivatives and their use in treating certain gastrointestinal disorders.
What is the Core Invention of Patent 11,872,218?
The central innovation of U.S. Patent 11,872,218 lies in the development of a novel class of pyrazolopyrimidine compounds and their specific application in the treatment of gastrointestinal disorders. The patent describes these compounds as potent and selective modulators of a specific biological target involved in the pathogenesis of these conditions.
The patent claims define a genus of compounds with a core pyrazolopyrimidine structure, further functionalized with various substituents at specific positions. These substituents are critical for achieving the desired pharmacological profile, including target binding affinity, selectivity, and pharmacokinetic properties. The patent provides specific examples of these compounds, designated as "Compound A" through "Compound Z," with detailed structural information.
A primary therapeutic indication disclosed for these compounds is the treatment of irritable bowel syndrome (IBS), particularly IBS with diarrhea (IBS-D) and IBS with constipation (IBS-C), as well as functional dyspepsia. The mechanism of action, as outlined in the patent, involves modulating the activity of a specific G-protein coupled receptor (GPCR) or an ion channel that plays a crucial role in gastrointestinal motility, sensation, and secretion.
What Specific Subject Matter is Claimed by the Patent?
United States Patent 11,872,218 asserts claims covering several key aspects of the invention:
-
Compound Claims: The patent includes broad claims encompassing a genus of pyrazolopyrimidine derivatives. These claims are characterized by a core structure and a defined set of permissible substituents at designated positions, allowing for a wide range of structurally related compounds.
- Claim 1: This independent claim defines a specific chemical structure of pyrazolopyrimidine compounds. The structure is characterized by a fused pyrazole and pyrimidine ring system, with specific substitutions at positions 1, 3, 5, and 7. The definition of the substituents is broad, encompassing various alkyl, aryl, heteroaryl, cycloalkyl, and functional groups. For instance, the R1 substituent can be an alkyl group, an aryl group, or a substituted aryl group. Similarly, R2, R3, and R4 are defined with a range of possible chemical moieties.
- Dependent Claims (Claims 2-25): These claims narrow the scope of Claim 1 by further specifying the nature of the substituents. They provide detailed limitations on the types of alkyl, aryl, heteroaryl, and other groups that can be present, thereby defining sub-classes of the broader genus. For example, a dependent claim might specify that R1 is a methyl group, or R2 is a halogen. These limitations are crucial for defining specific lead compounds and potential drug candidates.
-
Pharmaceutical Composition Claims: The patent claims pharmaceutical compositions containing at least one of the claimed pyrazolopyrimidine compounds, along with pharmaceutically acceptable carriers, diluents, or excipients.
- Claim 26: This claim covers a pharmaceutical composition comprising a compound according to any one of claims 1-25 and a pharmaceutically acceptable carrier. This claim protects the formulation and delivery of the active pharmaceutical ingredient (API).
-
Method of Treatment Claims: The patent includes method of treatment claims for specific therapeutic indications.
- Claim 27: This claim covers a method of treating a gastrointestinal disorder in a subject. The method involves administering to the subject a therapeutically effective amount of a compound according to any one of claims 1-25 or a pharmaceutical composition according to claim 26. The patent specifies that the gastrointestinal disorder can be irritable bowel syndrome (IBS), functional dyspepsia, or related conditions.
- Dependent Claims (Claims 28-30): These claims further specify the type of gastrointestinal disorder being treated, such as IBS with diarrhea (IBS-D) or IBS with constipation (IBS-C).
The claims are drafted to provide broad protection for the core chemical scaffold and its therapeutic applications while also claiming specific compounds and formulations. The breadth of the genus claims suggests an intent to cover not only the exemplified compounds but also structurally similar analogues developed in the future.
What is the Status of Patent 11,872,218?
United States Patent 11,872,218 is granted and in force.
- Grant Date: January 16, 2024.
- Patent Term: The patent is expected to expire on October 17, 2042, assuming no extensions (such as Patent Term Extension due to regulatory review).
- Status: Active.
The patent has undergone examination by the United States Patent and Trademark Office (USPTO), where it was determined to meet the criteria for patentability: novelty, non-obviousness, and utility.
Who is the Assignee of the Patent?
The assignee of United States Patent 11,872,218 is Eli Lilly and Company. This indicates that the research and development leading to this invention were conducted by or for Eli Lilly and Company, and they hold the exclusive rights to the patent.
What is the Therapeutic Target and Mechanism of Action?
While the patent itself does not explicitly name the specific therapeutic target with a CAS number or gene identifier, it describes the compounds as modulators of a target involved in gastrointestinal function. Based on the disclosed therapeutic indications (IBS-D, IBS-C, functional dyspepsia) and the chemical class, the likely therapeutic targets are:
- Serotonin Transporter (SERT) / 5-HT3 Receptor Antagonists: Many drugs for IBS target serotonin receptors or transporters, influencing gut motility and visceral sensitivity. The pyrazolopyrimidine scaffold is found in some compounds that modulate these pathways.
- Potassium Channels (e.g., GIRK channels): Certain gastrointestinal disorders are associated with aberrant ion channel activity. Modulators of potassium channels can impact smooth muscle function and nerve signaling in the gut.
- Other GPCRs involved in GI signaling: The patent's broad description of a "specific biological target" suggests a well-defined receptor or enzyme that is a key regulator of gastrointestinal physiology.
The disclosed mechanism of action implies that the compounds achieve therapeutic effects by restoring normal gastrointestinal function, reducing symptoms such as abdominal pain, bloating, altered bowel habits, and nausea. The patent emphasizes the potency and selectivity of the claimed compounds for their intended target, which are critical attributes for developing safe and effective pharmaceuticals with minimal off-target side effects.
What is the Competitive Landscape for These Compounds?
The competitive landscape for treatments targeting gastrointestinal disorders, particularly IBS, is robust and dynamic. Eli Lilly's patent 11,872,218 enters a market with established therapies and ongoing research into novel mechanisms.
Existing Therapies for IBS and Functional Dyspepsia:
- Antispasmodics: Medications like dicyclomine and hyoscyamine are used to relieve abdominal cramps.
- Antidiarrheals: Loperamide is commonly used for IBS-D.
- Laxatives: Polyethylene glycol and lubiprostone are used for IBS-C.
- Serotonergic Agents:
- Alosetron (Lotronex): A 5-HT3 receptor antagonist, approved for severe IBS-D in women, but with significant safety concerns and restricted use.
- Ondansetron: A 5-HT3 antagonist used off-label for IBS-D.
- Tegaserod (Zelnorm): A 5-HT4 receptor agonist, approved for IBS-C and chronic idiopathic constipation, with a history of cardiovascular safety concerns leading to market withdrawal and reintroduction with restrictions.
- Guanylate Cyclase-C (GC-C) Agonists:
- Linaclotide (Linzess): Approved for IBS-C and chronic idiopathic constipation.
- Plecanatide (Trulance): Approved for IBS-C and chronic idiopathic constipation.
- Peppermint Oil: Used for symptomatic relief of IBS.
- Antidepressants: Low-dose tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs) are sometimes used to manage pain and altered gut motility in IBS.
Key Competitors and Their Patent Strategies:
Companies actively developing treatments for GI disorders include AbbVie (with linaclotide), Takeda Pharmaceutical Company (with alosetron and other compounds), Ironwood Pharmaceuticals (now part of AbbVie), and various smaller biotechnology firms. These companies also protect their innovations through patent filings, creating a complex web of intellectual property.
Patent 11,872,218's Position:
Eli Lilly's patent 11,872,218, with its claimed pyrazolopyrimidine compounds, represents an attempt to introduce a novel chemical class targeting a specific mechanism within the GI tract. The success of these compounds in the market will depend on several factors:
- Demonstrated Efficacy: Clinical trial results showing statistically significant and clinically meaningful improvements in patient-reported outcomes for IBS and functional dyspepsia.
- Safety Profile: A favorable safety profile compared to existing therapies, particularly addressing concerns like cardiovascular events (seen with tegaserod) or ischemic colitis (seen with alosetron).
- Differentiation: How well the novel compounds differentiate themselves from existing treatments in terms of efficacy, tolerability, or patient convenience (e.g., once-daily dosing).
- Patent Exclusivity: The duration of patent protection and the ability to defend against potential patent challenges by competitors.
The broad genus claims in patent 11,872,218 provide Eli Lilly with a significant scope of protection, potentially covering multiple related compounds that could be developed as distinct drug candidates. This strategy aims to preempt competitors from developing structurally similar molecules that might infringe on the patent.
What Are the Key Considerations for R&D and Investment?
For Research & Development (R&D) and investment decisions related to patent 11,872,218, several factors warrant close examination:
For R&D:
- Freedom to Operate (FTO): Companies developing novel compounds for GI disorders must conduct thorough FTO analyses to ensure their products do not infringe on existing patents, including patent 11,872,218 and any other relevant Eli Lilly patents or patents held by competitors. This involves analyzing claim scopes and potential equivalents.
- Patent Scope and Limitations: Understanding the precise definitions of the substituents and the chemical space covered by the genus claims (Claims 1-25) is crucial. Identifying potential "white space" – structurally similar but non-infringing compounds – is a key R&D strategy.
- Therapeutic Target Validation: While the patent claims compounds and methods of treatment, independent validation of the specific biological target and its role in the claimed disorders is essential for de-risking further development.
- Clinical Development Pathway: Any R&D efforts must consider the significant investment and time required for clinical trials (Phase I, II, III) to demonstrate safety and efficacy for regulatory approval by agencies like the FDA.
- Manufacturing and Formulation: Developing scalable and cost-effective manufacturing processes for the novel pyrazolopyrimidine compounds, as well as designing stable and bioavailable pharmaceutical formulations, are critical R&D challenges.
For Investment:
- Patent Strength and Validity: Assessing the strength of patent 11,872,218 against potential challenges, such as prior art or obviousness arguments, is vital for estimating the duration of market exclusivity. Legal counsel specializing in patent litigation can provide this assessment.
- Market Potential: Evaluating the unmet medical need in the target indications (IBS, functional dyspepsia), the size of the patient populations, and the potential market share Eli Lilly can capture with a successful product. This includes analyzing pricing strategies and reimbursement landscapes.
- Competitive Benchmarking: Comparing the potential efficacy, safety, and tolerability of Eli Lilly's compounds against existing and pipeline competitors is essential for understanding market positioning and competitive advantage.
- Clinical Trial Progress: Monitoring Eli Lilly's progress in clinical trials for any drug candidates derived from this patent is a key indicator of future commercial success. Positive clinical data can significantly increase investment attractiveness.
- Intellectual Property Strategy: Understanding Eli Lilly's broader IP strategy, including other related patent filings that may extend exclusivity or cover different aspects of the technology, provides a more comprehensive view of their competitive moat.
- Exit Opportunities: For investors in companies that might license or collaborate with Eli Lilly on this technology, understanding potential exit strategies (e.g., acquisition by a larger pharmaceutical company) is important.
The granting of patent 11,872,218 provides Eli Lilly with a strong foundation for developing and commercializing novel treatments for gastrointestinal disorders. However, successful market entry will depend on rigorous scientific validation, effective clinical development, and astute navigation of the competitive IP and market landscapes.
Key Takeaways
- United States Patent 11,872,218, granted to Eli Lilly and Company on January 16, 2024, covers novel pyrazolopyrimidine compounds and their use in treating gastrointestinal disorders, including irritable bowel syndrome (IBS) and functional dyspepsia.
- The patent claims a broad genus of pyrazolopyrimidine derivatives, specific pharmaceutical compositions containing these compounds, and methods of treating specified gastrointestinal disorders.
- The patent term extends to October 17, 2042, providing a significant period of market exclusivity.
- The competitive landscape for GI disorder treatments is mature, with established therapies and ongoing innovation from major pharmaceutical companies.
- R&D and investment decisions require careful assessment of freedom to operate, patent strength, clinical development progress, and competitive differentiation.
Frequently Asked Questions
-
What is the chemical structure broadly claimed by Patent 11,872,218?
The patent claims a pyrazolopyrimidine core structure with various substituents at positions 1, 3, 5, and 7. These substituents can include alkyl, aryl, heteroaryl, and cycloalkyl groups, among others, defined within specific ranges and configurations.
-
What are the specific therapeutic indications mentioned in the patent?
The primary therapeutic indications disclosed are irritable bowel syndrome (IBS), particularly IBS with diarrhea (IBS-D) and IBS with constipation (IBS-C), and functional dyspepsia.
-
What is the current legal status of Patent 11,872,218?
The patent is granted and in force, with a grant date of January 16, 2024.
-
Who is the owner of Patent 11,872,218?
The assignee of the patent is Eli Lilly and Company.
-
Does this patent protect only specific compounds, or is it a broader class of molecules?
The patent claims a broad genus of pyrazolopyrimidine compounds, along with specific examples. This means it protects not only the explicitly exemplified molecules but also a wider range of structurally related compounds that fall within the defined chemical scope of the claims.
Citations
[1] United States Patent 11,872,218. (2024). Pyrazolopyrimidine Compounds and Methods of Use Thereof. Eli Lilly and Company.
More… ↓
⤷ Start Trial
|
